UCB Biosciences
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, UCB Biosciences sits in the top decile of US sponsors by registered trial count (#442 of 15,742 sponsors by registered trial count).
UCB Biosciences: 39 sponsored US clinical trials, none currently recruiting.
UCB Biosciences sponsors 39 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 33 completed. 23 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epilepsy, with 3 trials.
Top-decile sponsor footprint
UCB Biosciences ranks in the top decile of sponsors by registered trial count (#442 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
33 of 36 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
39 total, page 1 of 1
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
NCT06118255
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
NCT03845712
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
NCT07503444
A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
NCT06679413
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
NCT02710890
UCB Cimzia Pregnancy Follow-up Study
NCT02775656
Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects
NCT02806219
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
NCT02552212
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
NCT02408549
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
NCT02505542
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
NCT02477839
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
NCT02408523
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
NCT02154425
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
NCT01964560
Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures
NCT02088957
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
NCT02019602
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
NCT01782222
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
NCT01744496
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
NCT01711866
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
NCT01465997
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
NCT01537042
Pediatric Arthritis Study of Certolizumab Pegol
NCT01550003
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
NCT01495793
Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome
NCT01498120
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
NCT01339559
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
NCT01243177
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
NCT01296711
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
NCT01118962
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
NCT01118949
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT01087762
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
NCT01087788
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
NCT00938912
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
NCT00961441
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
NCT00844285
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
NCT00552344
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655486
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655551
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
NCT00520741
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00522275
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
| Phase 3 | 20 |
| Phase 4 | 3 |
How the UCB Biosciences archive is shaped
39 indexed studies, none listed as recruiting (0% open); 33 completed (85%).
Phase mix: 23 late (III/IV) vs 14 early (I/II) (later-stage heavy).
Top condition: Epilepsy (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
UCB Biosciences: archived-pipeline peers nationwide
Peers matched on 39 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
UCB Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 39 archived trials
- Ethicon Endo-Surgery · 39 trials · 3% recruiting
- James J. Peters Veterans Affairs Medical Center · 39 trials · 10% recruiting
- Maimonides Medical Center · 39 trials · 15% recruiting
- Northeastern University · 39 trials · 38% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this UCB Biosciences page
39 registered trials is a research-attention snapshot, not an endorsement of UCB Biosciences or any single study.
- None of UCB Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Epilepsy is the condition UCB Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epilepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. UCB Biosciences pipeline card: 39 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.